Total Payments
$1.8M
2024 Payments
$250,698
Companies
54
Transactions
1,637
Medicare Patients
495
Medicare Billing
$70,926
Payment Breakdown by Category
Other$921,025 (50.6%)
Consulting$523,409 (28.8%)
Travel$222,605 (12.2%)
Research$119,885 (6.6%)
Food & Beverage$31,966 (1.8%)
Education$230.01 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $920,800 | 310 | 50.6% |
| Consulting Fee | $523,409 | 215 | 28.8% |
| Travel and Lodging | $222,605 | 390 | 12.2% |
| Unspecified | $119,885 | 87 | 6.6% |
| Food and Beverage | $31,966 | 630 | 1.8% |
| Education | $230.01 | 4 | 0.0% |
| Honoraria | $225.00 | 1 | 0.0% |
Payments by Type
General
$1.7M
1,550 transactions
Research
$119,885
87 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $688,170 | 398 | $0 (2024) |
| United Therapeutics Corporation | $381,242 | 527 | $0 (2024) |
| Genentech USA, Inc. | $253,101 | 204 | $0 (2022) |
| F. Hoffmann-La Roche AG | $221,360 | 131 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $47,376 | 69 | $0 (2024) |
| Merck Sharp & Dohme LLC | $41,420 | 56 | $0 (2024) |
| Hoffmann-La Roche Limited | $31,451 | 12 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $27,824 | 16 | $0 (2024) |
| Actelion Pharmaceuticals, Ltd | $20,013 | 22 | $0 (2022) |
| AstraZeneca UK Limited | $18,269 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $250,698 | 289 | Boehringer Ingelheim Pharmaceuticals, Inc. ($116,163) |
| 2023 | $213,022 | 212 | United Therapeutics Corporation ($100,520) |
| 2022 | $185,268 | 195 | United Therapeutics Corporation ($80,957) |
| 2021 | $193,457 | 158 | Boehringer Ingelheim Pharmaceuticals, Inc. ($81,996) |
| 2020 | $176,995 | 95 | Boehringer Ingelheim Pharmaceuticals, Inc. ($61,874) |
| 2019 | $322,891 | 242 | Boehringer Ingelheim Pharmaceuticals, Inc. ($140,577) |
| 2018 | $231,942 | 239 | Genentech USA, Inc. ($83,943) |
| 2017 | $244,848 | 207 | Boehringer Ingelheim Pharmaceuticals, Inc. ($86,084) |
All Payment Transactions
1,637 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | United Therapeutics Corporation | Steen Solution (Device) | — | Cash or cash equivalent | $7,975.00 | Research |
| Study: Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility • Category: Lung Diseases | ||||||
| 12/24/2024 | United Therapeutics Corporation | Steen Solution (Device) | — | Cash or cash equivalent | $42.55 | Research |
| Study: Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility • Category: Lung Diseases | ||||||
| 12/24/2024 | United Therapeutics Corporation | Steen Solution (Device) | — | Cash or cash equivalent | $35.00 | Research |
| Study: Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility • Category: Lung Diseases | ||||||
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: RESPIRATORY | ||||||
| 12/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Cardio-pulmonary | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $6,685.00 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | United Therapeutics Corporation | TYVASO (Drug) | Consulting Fee | Cash or cash equivalent | $870.00 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 12/09/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $49.97 | General |
| Category: Infectious Diseases | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $955.00 | General |
| 12/03/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,210.00 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | Mylan Specialty L.P. | TOBI PODHALER (Drug) | Food and Beverage | In-kind items and services | $38.50 | General |
| Category: Aminoglycosides | ||||||
| 11/21/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Vabomere | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: ANTIFUNGALS | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $123.32 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,270.00 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $439.45 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $419.84 | General |
| 11/19/2024 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), CT THROMBECTOMY SYSTEM KIT | Food and Beverage | In-kind items and services | $205.48 | General |
| Category: VTE | ||||||
| 11/13/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $475.00 | Research |
| Study: An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis • Category: Idiopathic Pulmonary Fibrosis | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 11/07/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | United Therapeutics Corporation | $41,707 | 17 |
| A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE | United Therapeutics Corporation | $14,048 | 12 |
| Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility | United Therapeutics Corporation | $8,053 | 3 |
| A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF GROUP 3 PULMONARY HYPERTENSION | F. Hoffmann-La Roche AG | $6,698 | 7 |
| Using Forced Vital Capacity in the Clinic to Monitor Patients With Idiopathic Pulmonary Fibrosis Pros and Cons | F. Hoffmann-La Roche AG | $6,050 | 1 |
| OPTIMISING THE SIX-MINUTE WALK TEST AS A PRIMARY ENDPOINT IN INTERSTITIAL LUNG DISEASE CLINICAL TRIALS WALK ALONE OR COMPANION FOR A COMPOSITE | F. Hoffmann-La Roche AG | $5,340 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3, THREE-ARM STUDY OF THE SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS, A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | F. Hoffmann-La Roche AG | $4,748 | 2 |
| An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies | F. Hoffmann-La Roche AG | $3,830 | 2 |
| A PHASE IIB, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF GROUP 3 PULMONARY HYPERTENSION | F. Hoffmann-La Roche AG | $3,109 | 4 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IPF | F. Hoffmann-La Roche AG | $2,851 | 8 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis, A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | F. Hoffmann-La Roche AG | $2,446 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | F. Hoffmann-La Roche AG | $2,412 | 2 |
| SIX-MINUTE WALK TEST AS A PRIMARY END-POINT IN INTERSTITIAL LUNG DISEASE | F. Hoffmann-La Roche AG | $2,052 | 1 |
| Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized Phase III STARSCAPE trial | F. Hoffmann-La Roche AG | $2,049 | 1 |
| A PHASE 3 OPEN-LABEL EXTENSION TRIAL TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IPF | F. Hoffmann-La Roche AG | $1,472 | 4 |
| A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | United Therapeutics Corporation | $1,164 | 8 |
| An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | United Therapeutics Corporation | $950.00 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3, THREE-ARM STUDY OF THE SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | F. Hoffmann-La Roche AG | $889.00 | 1 |
| Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis | F. Hoffmann-La Roche AG | $403.33 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 130 | 181 | $72,903 | $20,920 |
| 2022 | 5 | 144 | 199 | $70,569 | $22,167 |
| 2021 | 3 | 115 | 150 | $52,951 | $17,009 |
| 2020 | 3 | 106 | 140 | $44,475 | $10,830 |
Total Patients
495
Total Services
670
Medicare Billing
$70,926
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 86 | 135 | $52,448 | $15,538 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $14,969 | $4,223 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 19 | $5,486 | $1,158 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 75 | 109 | $40,330 | $13,322 | 33.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 34 | $8,798 | $2,895 | 32.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $7,392 | $2,133 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $7,174 | $1,967 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 23 | 25 | $6,875 | $1,850 | 26.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 56 | 80 | $30,255 | $10,115 | 33.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 56 | $15,216 | $4,516 | 29.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $7,480 | $2,377 | 31.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 49 | 67 | $23,584 | $5,326 | 22.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 45 | 61 | $16,043 | $4,199 | 26.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $4,848 | $1,305 | 26.9% |
About Dr. Steven Nathan, MD
Dr. Steven Nathan, MD is a Internal Medicine healthcare provider based in Falls Church, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891724134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Nathan, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $250,698 received in 2024. These payments were reported across 1,637 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($920,800).
As a Medicare-enrolled provider, Nathan has provided services to 495 Medicare beneficiaries, totaling 670 services with total Medicare billing of $70,926. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Falls Church, VA
- Active Since 06/30/2006
- Last Updated 05/11/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1891724134
Products in Payments
- OFEV (Drug) $503,677
- Esbriet (Biological) $487,437
- TYVASO (Drug) $201,856
- Adempas (Drug) $47,376
- Letairis (Drug) $12,274
- Steen Solution (Device) $8,077
- NONE (Drug) $7,238
- KEYTRUDA (Biological) $7,025
- ORENITRAM (Drug) $6,673
- MK-5475 (Drug) $5,650
- Non-Covered Product (Drug) $5,168
- ENHERTU (Biological) $4,143
- UPTRAVI (Drug) $2,510
- Xolair (Biological) $2,262
- GLASSIA (Biological) $2,051
- WINREVAIR (Biological) $1,155
- Non-Covered Product $660.00
- REMODULIN (Drug) $504.64
- MK-6158 (Drug) $406.25
- FLOWTRIEVER CATHETER, S (Device) $382.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Falls Church
Amit Mahajan, M.d, M.D
Internal Medicine — Payments: $796,635
Internal Medicine $796,635
Dr. Kevin Donohue, D.o, D.O
Internal Medicine — Payments: $726,727
Internal Medicine $726,727
Sami Abdul Jawad, M.d, M.D
Internal Medicine — Payments: $212,772
Internal Medicine $212,772
Jeanny Aragon-Ching, M.d, M.D
Internal Medicine — Payments: $204,935
Internal Medicine $204,935
Dr. Christopher King, Md, MD
Internal Medicine — Payments: $130,932
Internal Medicine $130,932
Joseph Krepp, M.d, M.D
Internal Medicine — Payments: $74,286
Internal Medicine $74,286